/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Enanta Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$14.24 0.0201(2.01%) ENTA at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 14.05
Highest Today 14.46
Today’s Open 14.28
Prev. Close 13.96
52 Week High 15.34
52 Week Low 4.09
Day’s Range: Low 14.05 High 14.46
52-Week Range: Low 4.09 High 15.34
1 day return -
1 Week return +1.06
1 month return +31.3
3 month return +61.49
6 month return +100.56
1 year return +67.37
3 year return -67.06
5 year return -66.55
10 year return -

Institutional Holdings

Farallon Capital Management, L.L.C. 9.93

Krensavage Asset Management, LLC 9.89

Vanguard Group Inc 9.25

BlackRock Inc 8.64

Millennium Management LLC 6.82

Marshall Wace Asset Management Ltd 4.01

Vanguard Total Stock Mkt Idx Inv 2.88

Stonepine Capital Management Llc 2.83

HHG PLC 2.45

Geode Capital Management, LLC 2.27

iShares Russell 2000 ETF 2.22

State Street Corp 2.20

Renaissance Technologies Corp 2.20

AQR Capital Management LLC 1.85

Vanguard Strategic Small-Cap Equity Inv 1.58

Morgan Stanley - Brokerage Accounts 1.34

D. E. Shaw & Co LP 1.32

Dimensional Fund Advisors, Inc. 1.30

Trexquant Investment LP 1.24

Northern Trust Corp 1.18

Vanguard Institutional Extnd Mkt Idx Tr 0.98

Vanguard VIF Small Co Gr 0.96

Fidelity Small Cap Index 0.94

Jacobs Levy Equity Management, Inc. 0.90

iShares Russell 2000 Value ETF 0.86

Vanguard Strategic Equity Inv 0.85

Sio Capital Management, LLC 0.84

Charles Schwab Investment Management Inc 0.77

UBS (Lux) EF Biotech (USD) P-acc 0.75

Vanguard Explorer Inv 0.56

iShares Biotechnology ETF 0.56

BlackRock Advantage Small Cap Core Instl 0.51

Fidelity Extended Market Index 0.51

Vanguard Russell 2000 ETF 0.45

Schwab US Small-Cap ETF™ 0.43

JPMorgan Small Cap Value I 0.35

Acadian Global Small-Cap Equity CIT Cl A 0.34

State St Russell Sm Cap® Indx SL Cl I 0.34

Dimensional US Small Cap ETF 0.27

Schwab Small Cap Index 0.25

Market Status

Strong Buy: 2

Buy: 1

Hold: 2

Sell: 1

Strong Sell: 0

Fundamentals

Market Cap 402.79 M

PB Ratio 6.2973

PE Ratio 0.0

Enterprise Value 276.58 M

Total Assets 280.73 M

Volume 268579

Company Financials

Annual Revenue FY25:65324000 65.3M, FY24:67635000 67.6M, FY23:79204000 79.2M, FY22:86160000 86.2M, FY21:97074000 97.1M

Annual Profit FY25:65324000 65.3M, FY24:67635000 67.6M, FY23:79204000 79.2M, FY22:86160000 86.2M, FY21:97074000 97.1M

Annual Net worth FY25:-81889000 -81.9M, FY24:-116045000 -116.0M, FY23:-133816000 -133.8M, FY22:-121755000 -121.8M, FY21:-78996000 -79.0M

Quarterly Revenue Q3/2025:15125000 15.1M, Q2/2025:18314000 18.3M, Q1/2025:14926000 14.9M, Q4/2024:16959000 17.0M, Q3/2024:14607000 14.6M

Quarterly Profit Q3/2025:15125000 15.1M, Q2/2025:18314000 18.3M, Q1/2025:14926000 14.9M, Q4/2024:16959000 17.0M, Q3/2024:14607000 14.6M

Quarterly Net worth Q3/2025:-18700000 -18.7M, Q2/2025:-18255000 -18.3M, Q1/2025:-22644000 -22.6M, Q4/2024:-22290000 -22.3M, Q3/2024:-28823000 -28.8M

Fund house & investment objective

Company Information Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 120

Industry Biotechnology

CEO Dr. Jay R. Luly Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow